ZNF697

Across TCGA pan-cancer cohorts, ZNF697 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ZNF697 data layer compared with 28 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ZNF697 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF697 expression acts as an unfavorable survival marker, although some lineages such as STAD and SKCM show a favorable association.

SCLC, LIHC, and ESCA are the cancer types where ZNF697 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	All	0.082	0.708	<.001	36	view →
LIHC	OS	Median	All	0.145	0.786	<.001	36	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	15	view →
COAD	DFS	Median	All	0.435	0.797	.005	10	view →
STAD	DFS	Median	All	1.000	0.391	.042	6	view →
HNSC	DFS	Median	IV	0.078	0.670	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.670	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ZNF697–SCLC (OS)

Open the SCLC breakdown →